drugset / Trial / NCT02889848

Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)

NCT02889848

Phase 1 Completed 15 enrolled Advance Biofactures Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This pilot study evaluates the safety and tolerability of a single injection of collagenase enzyme directly into a uterine fibroid in subjects already selected for hysterectomy or myomectomy. Fibroids contain excessive amounts of collagen and it is possible that digestion of collagen may be beneficial in reducing pain and bleeding associated with fibroids. Three subjects will be injected with saline only to evaluate the safety and effectiveness of the injection method. Additional subjects will then be injected with increasing doses of study drug.

Timeline

Start
2016-10-27
Primary completion
2018-10-05
Completion
2018-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 0.05 mg/ml Other
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 0.1 mg/ml Other
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 0.2 mg/ml Other
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 1.16 mg Other

Indications